|Bid||30.51 x 1000|
|Ask||31.29 x 800|
|Day's Range||30.42 - 32.20|
|52 Week Range||19.00 - 34.37|
|Beta (5Y Monthly)||2.61|
|PE Ratio (TTM)||N/A|
|Earnings Date||Feb 25, 2020 - Mar 01, 2020|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||46.71|
Axsome Therapeutics is on a tear this year - with shares skyrocketing over 3,000%. This comes as the biotech company's migraine drug posted successful results in a late-stage study. Yahoo Finance's Anjalee Khemlani joins Seana Smith on The Ticker to discuss.
The saga over who owns the valuable patents that cover CRISPR/Cas9 gene editing took a new turn this week with a court decision that goes against the Broad Institute of Harvard and MIT and two local startups.
In a presentation to investors on Wednesday, January 15, 2020, at 10:30 a.m. PST at the 38th Annual J.P. Morgan Healthcare Conference, Editas Medicine, Inc. (EDIT) President and CEO Cynthia Collins will discuss the Company’s progress on developing in vivo and engineered cell medicines and building the leading genomic medicine company.
CAMBRIDGE, Mass. and DALLAS, Jan. 13, 2020 -- Editas Medicine, Inc. (Nasdaq: EDIT), a leading genome editing company, and Sandhill Therapeutics, Inc., a cellular.
CAMBRIDGE, Mass., Jan. 10, 2020 -- Editas Medicine, Inc. (Nasdaq: EDIT), a leading genome editing company, today announced the grant of inducement awards to the Company’s newly.
Editas Medicine, Inc. (EDIT), a leading genome editing company, today announced the appointment of Michelle Robertson as the Company’s Chief Financial Officer, and the appointment of Harry Gill in the newly created role of Senior Vice President, Operations, both effective immediately.
The first humans will have Crispr deployed like a drug inside their bodies this year, as companies embark on a new stage of the gene-editing revolution that could lead to many more diseases being treated, or even cured, with the technology. Last year, the first trial used Crispr to edit blood cells that were taken out of and then returned to a body.
Editas (EDIT) progresses well on developing its lead candidate EDIT-101 to treat LCA10, a rare genetic illness that causes blindness. Excessive reliance on partners for revenues remains a concern.
CAMBRIDGE, Mass., Jan. 02, 2020 -- Editas Medicine, Inc. (Nasdaq: EDIT), a leading genome editing company, today announced that it will present a company overview followed by a.
Shares of CRISPR gene-editing companies tumbled Monday after the Chinese scientist who created the world's first genetically edited babies was sentenced to three years behind bars.
By buying an index fund, you can roughly match the market return with ease. But if you choose individual stocks with...
We know that hedge funds generate strong, risk-adjusted returns over the long run, therefore imitating the picks that they are collectively bullish on can be a profitable strategy for retail investors. With billions of dollars in assets, smart money investors have to conduct complex analyses, spend many resources and use tools that are not always […]
Editas Medicine, Inc. (EDIT), a leading genome editing company, today announced in vivo proof-of-concept data supporting the development of EDIT-301 as a potentially best-in-class, durable medicine to treat sickle cell disease and beta-thalassemia. EDIT-301 is the first experimental medicine in development using Cas12a (formerly known as Cpf1). The Company reported these data today at the 61st Annual Meeting and Exposition of the American Society of Hematology (ASH) in Orlando, Fla.
Vertex (VRTX) and partner CRISPR Therapeutics announce positive early data from two studies on gene-editing drug CTX001 for the treatment of beta-thalassemia and sickle cell disease.
CRISPR Therapeutics and Vertex Pharmaceuticals released the first data from their early-stage trial testing the safety and effectiveness of a potential cure for the genetic blood disorders sickle cell disease and beta thalassemia.
Editas (EDIT) delivered earnings and revenue surprises of 9.59% and -6.38%, respectively, for the quarter ended September 2019. Do the numbers hold clues to what lies ahead for the stock?
Amended Celgene collaboration to focus on engineered alpha-beta T cell medicines with a $70 million payment to Editas Medicine Appointed Judith R. Abrams, M.D., as Chief.